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The percentage of urological cancers is considerable. Of all of the cancer deaths in our country, 10%
are urological; in men alone, 18% are urological. It is
immediately obvious that a very important aspect of
this specialty is the treatment of cancer.
Of the 18 % urological deaths among males,
more than half are due to cancers of the prostate.
When a patient is seen with evidence of a metastasizing cancer and a search is made for the primary
site or source, there is always a hope that it will
be cancer of the prostate, because we can do a
great deal for this cancer that cannot be done in
many other cancers.
A comparison of the various urological cancer
deaths will show that cancer of the prostate is the
most frequent. Second is carcinoma of the bladder,
followed by kidney tumors. In comparing cancer of
the prostate with other cancers in older men (men
over 75), prostatic carcinoma is the most common
cause of cancer deaths. If figures for cancer of the
colon, rectum and stomach are combined, the resulting figure is slightly in excess of that for prostatic
tumors. The impressive fact is that cancer of the
prostate is the most significant cause, makes the
most widows, of all the cancers among older males.
With every passing decade, the number of cancers
that one finds in any autopsy series of older people
increases steadily. It does not increase among the
people with cirrhosis, perhaps because of the increased circulating estrogens in older people who
have hepatic cirrhosis. If men were to live for an
indefinite period of time, practically all of them would
die of cancer of the prostate. The secret weapon is
the rectal examination to detect the prostatic nodule
before it has developed to a more advanced stage.

* This is a transcription, edited by Dr. Warren W.
Koontz, Jr., of a lecture presented by Dr. Lattimer at the
26th Annual Stoneburner Lecture Series, February 22,
1973, at the Medical College of Virginia, Richmond.
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Dr. Charles Huggins' classic cross sections of the
prostate ( 4) showed that the cancerous, dark area
is almost always in the posterior lamella against the
rectum where the rectal finger can easily palpate the
nodule. It is universally recognized that rectal palpation of the nodule will disclose cancer in only 50%
of the cases. Nevertheless, in the 50% where cancer
exists, the extent of the cancer is usually more than
one would suspect from what one can feel. Recently,
I have had it brought to my attention very forcefully
that an asymmetry of the prostate without any particular increase in firmness may be worthy of great
attention. I have had several patients who related that
their internist had detected an asymmetry two or
three years prior to biopsy and diagnosis. The instrument we use for biopsies is one developed by Dr.
Ralph Veenema.
This instrument can be used with local anesthesia, but it is much easier with pentothal anesthesia. We prefer the Veenema instrument,
however, since it gives a substantial fragment of tissue as compared to the Silverman or Vim-Silverman
needle biopsies. Inadequate specimens may prevent
the pathologist from rendering a diagnosis. We also
want larger fragments because we grow the biopsies
in tissue culture. This gives not only a dimension of
additional size, but also gives an opportunity to
experiment with that patient's cancer to see what
medications act best against it and to see how it
might differ from others.
Of the prostate tumors biopsied, 11 % were
confined to the prostate. Bone scans, bone surveys,
and marrow acid phosphatases have shown that
55% of the prostate cancers have extended locally.
There is still another substantial group that has
extended beyond the confines of the pelvis. The
treatment varies in these different groups. It is the
first group that is amenable to radical excision;
the second group may be amenable to radiotherapy
plus hormone therapy. For the third group, one must
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depend upon hormone therapy and hopefully, in the
next few years, immunotherapy.
Only 13 % of patients with prostatic cancer
were detected at an operable stage. The periodic rectal examination is a campaign which we must all
wage. It affords the greatest chance of success for
making a contribution in preventive medicine. The
executive physical examinations that many companies sponsor is one of the best programs in the
area of prevention. Occasionally, we find cancer in
the chips from a transurethral prostatectomy which
we did not suspect from rectal palpation. Then we
have the dilemma of whether cancer has been left in
the capsule, and we may resect a little more after
a while to see whether we have chips. A few patients
have undergone radical prostatectomy. Since radical
prostatectomy is difficult technically following transurethral prostatectomy, we resort to radiotherapy
plus hormones or just hormones alone. Following
radical prostatectomy, we administer antiandrogen
treatment in the form of castration and estrogens
for every patient who will take what we consider to
be our best advice. We have a substantial number of
cases treated in this way and are awaiting the 20year follow-up to compare with surgery alone.
When suprapubic or retropubic enucleation reveals cancer, we are better able to determine whether
all of the tumor has been removed. If so, there is no
need to go back and do a radical procedure. Frequently, when the patient has been through a big
operation, he is not anxious to undergo further
operative therapy. We are building some experience
with radiotherapy after enucleation. One of our worries was that strictures might be more common and
indeed be a bad feature of this type of therapy, but
this has not turned out to be true.
We prefer the radical retropubic prostatectomy.
We do not perform radical perineal prostatectomies
except for instructional purposes or for a particular
case where it seems to be indicated. With the radical
perineal prostatectomy, there is no opportunity to investigate for nodal metastasis.
The first and classical study that Nesbit and
his group ( 5) compiled indicated that stilbestrol increased the five-year survival of patients with prostatic cancer. Orchidectomy was a little better and
the combination was better than either one alone.
The Veterans Administration report (2) has indicted stilbestrol therapy as a cause of coronary
artery disease, phlebitus, and perhaps cerebral artery
disease. In the wave of shock and enthusiasm on
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their part they have gone overboard and have discouraged a number of physicians from using stilbestrol.
Castration, however, is a more certain way of
obtaining an antiandrogenic effect and has none of
the drawbacks that stilbestrol itself might have. We
combine hormone therapy, or antiandrogens with
castration. Castration is not of great importance to
most of our patients. Their sex life has almost ended
by the time we see them for their cancers, and they
do not mind trading a better life expectancy for
castration. Bony metastases of considerable extent
will clear remarkably with antiandrogen treatment,
and likewise, pulmonary metastases have cleared.
Drawing on Dr. Huggins' experience (3), we
have an interesting bit of information. A patient with
metastases from a cancer of the prostate, proven by
biopsy, was given stilbestrol by Dr. Huggins. He was
left with just one or two metastases. Dr. Huggins
then performed an orchidectomy and the nodules
disappeared. Thi.Is we have two different modes of
action with these two agents. A combination will be
more effective than either one alone. It is not just
an additive but it is a different action.
A patient with cancer of the prostate which had
obstructed the ureter was benefited by radiotherapy
in shrinking the prostate. He was given 6,000 r of
radiotherapy to the prostate area and the obstruc~
tion was relieved. The enthusiasts for this particular
method of therapy, and particularly Dr. Malcolm
Bagshaw ( 1), have put together a very large number
of patients treated more or less with radiotherapy
alone. Their success rate has been so good that
they tell us that radiotherapy is curative. Raimey
( 6), however, has produced at least a dozen cases
where he has biopsied the prostate after radiotherapy
and the cancer appeared exactly as before radiotherapy. He argues that the cancer is not cured.
Bagshaw replies that it looks like cancer but is not
cancer and will not grow. Time will tell whether
radiotherapy is really effective. Supervoltage therapy
and perhaps larger doses and better targeting are
improving results and the question is whether radiotherapy is as good as radical prostatectomy.
The Veterans Administration study suggests that
conservative therapy is as good as radical surgery,
but my view, after reviewing all of the studies, is
that we do not yet know whether radiotherapy is indeed as good.
The next question concerns combining radiotherapy with antiandrogen therapy. Will that be as
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good as a radical operation? At this moment, we do
not know. We do know that if we remove the tumor,
at least we are rid of the major part of the focus.
The question remains, what about the cells that are
spilled or that have migrated away? In reply to that
question, one can demonstrate various experiments
where a large mass of cancer treated by any modality
has no great chance of shrinking. If the large
tumor mass is removed and you leave behind only a
few cells, then you may indeed kill those few cells
by whatever supplementary means you use. We must
look in the future to taking out the mass of cancer
and then successfully treating what is left behind
by immunological, hormonal means or by x-ray. We
must think in terms of combination, and in my mind
it is not entirely clear whether the radiation therapy
plus hormone treatment is as good as surgery alone
or surgery plus hormone treatment.
Occasionally, there will be a massive cancer
and the resectoscope will be necessary to tunnel an
opening through it. This can be done and supplemented by other treatments. Another modality for
this problem is freezing the prostate. We insert a
cryoprobe much in the same location as the resectoscope sheath. The temperature is dropped to minus
170° F and the mass of prostate freezes completely
solid. It looks like a ball of ice, and literally, it is a
ball of ice. Over the course of the next few weeks,
the prostate will then slough. A catheter may have to
remain in place for quite a long time while the gelatinous slough is removed. Later, there will be a very
satisfactory tunnel through the middle of the prostate, whether it is benign or malignant.
There has been some suggestion that the very
act of freezing will set up an immune reaction in
the body wherein the body will attempt to reject, not
only the frozen prostate, but also perhaps the metastases. There is some encouraging evidence of this,
and we have research going on presently in this field.
We have been freezing the prostate three times, a
so-called triple-freeze, and this is alleged to improve
the immunological response and is a new dimension
that is worth testing. It is not certain that it will be
as good as we would like but, nevertheless, bone pain
does diminish.
If the prostate tumor appears to be resectable,
we prefer to use the suprapubic approach. Our operation involves dividing the uretha just beyond the
apex, dividing the vasa, dissecting the seminal vesicles down to their tips and dividing the vessels.
We take the fascia around the seminal vesicles pur-
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posely because we have found that this is the first
route of extension of the disease outside of the
prostate. We also remove a cuff of bladder.
We take pieces of tissue from a benign area
and pieces from the cancerous area and grow them
in a medium that is laced with radioactive food in
the form of thymidine and cytidine. We then make a
radioautograph of this and determine the DNA and
RNA synthesis rates in these various areas. We find
a very clear picture of benign activity in the benign areas and a very clear picture of greater activity (five or six times as much mitosis) in the cancerous area. Dr. Myron Tannenbaum, one of our
researchers, has found that the area surrounding the
cancer was as active as the cancerous area. This surprised him, and he then subjected the cells from this
area to a higher magnification and discovered some
very interesting material in what we refer to as the
demilitarized zone, just outside the cancer.
The cancers of the prostate are histologically
so much like cancers of the breast that we run a
lot of parallel work in the two fields. Dr. Tannenbaum looked at cancers of the breast and found the
same virus-like material in them. Turned on edge,
the rods of the material look more target-like. Looking at the cancers themselves in both the breast and
in the prostate, he found the virus-like material in
the lumen of the prostate and the breast. A different
kind of virus-like particle, the so-called "C" particle
has been found in the milk of a mouse with breast
cancer as well as in the semen of her mate. A similar
"C" particle has been found in the semen of one of
our patients with cancer of the prostate. We are now
heavily involved in antibody testing of all of our patients and their wives to see if there is any possible
relationship between cancers of the prostate in men
and cancer of the breast or genitalia in their wives.
We studied 5,000 men and found 186 men with
cancer of the prostate, where the wife had been living
and having intercourse with him for at least two
years before the diagnosis of cancer of the prostate
was made. We found 8-9% of the wives of those patients had cancer of the breast. When one compares
this with the expected incidence of such a group, it is
500 times more. From this very carefully controlled
group, it was found that the controls had an incidence of less than 1 %-a finding of more than just
passing interest. From this work we now advise that
all of the wives of patients with cancer of the prostate
have a very. careful breast examination, cervical Pap
smear and ovarian examination at least every six
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months. We have been cautious about stirring up a
lot of anxiety where it might be unfounded, but
knowing these facts and saying nothing would not be
right either. We consider it advisable to be cautious
in the campaign of encouraging the wives of men
with cancer of the prostate to be examined more
carefully and conscientiously than wives in the general population.
It is possible to take a time-lapse picture of a
cancer cell and see what happens as it begins to
divide. First, a refractive outer coat appears as the
cell goes from the resting configuration to the stage
where it is about to divide. The chromosomal material begins to shape into a spindle and starts to divide. Then the spindle forms very decidedly and
some minutes later, there are two sets of chromosomes, divided and beginning to pull apart. They
pull apart further, and two cells begin to form, now
having a configuration more like the resting phase.
If you know how many frames per second or per
minute are involved in these changes, you can time
the intervals between each of these phases. We
usually take two-to-four frames per minute. The cancer cells take longer to divide than the normal cells,
but the cancer cells go through this procedure much
more often than the normal cells. An eye dropper
can be used to add various anticancer medications
to the culture to see how the course of events can be
influenced. If the mitotic process stops, one can see
in what phase it stops. The anticancer agents can
be labeled and observed as they go into the cell. If
the particles are fine enough and are hooked up to
an immunological apparatus, it is possible to discover
where they went in the cell. The technical aspects of
this procedure pertain to the fact that some drugs
go into the cell wall, some into the mitochondria,
some into the nucleus, and other drugs act on the
nucleolus. If one is using multiple drugs, it is helpful
to have different modes of action. We have done this
with the Wilms' tumor drugs and have sorted them to
determine the actions of the different medications and
have been able to obtain some information about the
different modes of action and the most effective combinations. In spite of this technical apparatus, we
still find the most important single case-finding factor influencing the successful treatment of this prostate cancer to be the periodic rectal examination.
Another aspect of scientific advancement is the
fact that the cancers have caused the development
of various immunological changes in the blood
stream. Sometimes various antigens and antibodies
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are present. There has been a rekindling of enthusiasm about this. Certain carcinomas of the bowel
and certain embryological pieces of bowel give off
antigens into the blood that can be measured quite
easily. We have discovered that in various urological
cancers this same antigen, called a cancer-associated
antigen or a carcinoma embryonic antigen, is detectable. We have demonstrated that in various samples
of prostate from various samples of the patient population, we would find an increased and measurable
amount of tumor-associated antigen that would not
be of any value as a screening test because it was not
always positive. Yet it did have value as a test of
failure of treatment. If one surgically removed the
prostate in a cancer patient and the test became
negative, that was a good sign. If the test remained
positive following surgery, one would know that all
of the tumor had not been removed. Therefore, one
might be more vigorous with the antiandrogenic or
irradiation treatments. We have used it as an index
of failure in radiotherapy cases where the first portal
was mapped out and treatment included the prostate
only. If the test remained positive, then we knew we
had failed to kill all of the cancer arid we then
irradiated to a larger field. Thus the test does have
some usefulness even in its present crude form. The
obvious implications are that we may be able to
develop an antigenic test specifically for the prostate.
This is what we are working on and I am sure others
are investigating it also. This field is of considerable
importance and interest.
We have used the same tumor-associated antigen, hooking it onto a bridging-type of enzyme substance, onto which can be hung a color, namely a
reddish-brown color. If the tumor is positive with
this antigen, we can treat the patient with this matedal and the cancerous areas will turn a very
distinctive color. In a lymph node where the cancer
is not obvious and where, by ordinary investigation,
that is light microscopy, it may not be possible to tell
that these areas are cancerous, this test will show
that the node is very specifically cancerous.
The same technique might be applied to the
Pap smear to ascertain whether there are cancerous
cells in tissues. With the electron microscope, one can
tell for sure, but you cannot scan wall-to-wall with
the electron microscope. With the antigen, it would
be possible to pinpoint the areas that turned red and
go directly to them with the electron microscope.
We may be able to apply our greater scientific capability to the clinical staging of the cancer and thus
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bring about a more specific and accurate staging
and treatment. The implications of this are considerable.
Our only protection against cancer of the prostate and its rapid growth is the annual physical
examination. We know that various cancers divide
at different rates. We do not know the reasons for
all of the differences. We do not even know why one
person develops a prostatic cancer and the next does
not. The fact that it is endocrinologically dependent,
the fact that it is possible to survey what goes on in
great detail through the capabilities that we have
makes the urological specialty very valuable in the
cancer area.
We are able to study the rate of growth, regression or improvement of solid tumors of the kidney through pyelography, aortography and angiography better than other fields. Epithelial tumors of
the bladder can be observed with the cytoscope and
biopsied periodically to follow the efficacy of treatment or to get specimens for study. Hormone-dependent therapy in cancer of the prostate gives us more
leverage and opportunity to study the activity of
cancer. The advances that have been accomplished,
in fact some of the great success stories of cancer,
have been urological. I think the prostate was certainly the bellwether of all the demonstrations that
a hormone-dependent cancer could be influenced. I
think it is part of our responsibility as urologists to
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realize that we have this opportunity. I know that all
of you share with me this enthusiasm to do everything we can and to be in a position for contributing
more than any other specialty to the study of cancer.
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